Robles BioCeutics’ PCT patent application directed to pioneering injury-mimetic stem cell and exosome platform.
SAN DIEGO, Sept. 24, 2025 /PRNewswire/ — Robles BioCeutics, the inventors of the “Injury Mimetic™” approach to stem cell and exosome mediated skin rejuvenation, announced the filing of a PCT patent application protecting the scientific and mechanistic basis of its flagship product, GlowSelle™.
The PCT patent application discloses new data demonstrating enhancement of angiogenic, regenerative, and anti-inflammatory activities of various stem cells through exposure of cells to biological signals that replicate injury.
The PCT patent application, prepared and filed in collaboration with Knobbe Martens and patent attorney Jason Jardine, is directed to Robles BioCeutics’ breakthrough method of replicating injury signals in vitro to enhance the potency of stem cell secretomes. This approach enables GlowSelle™ to deliver a richer symphony of growth factors and exosomes — a key differentiator from conventional stem cell–based products — while reinforcing the Company’s intellectual property portfolio as it advances toward clinical validation and commercialization.
“Collaborating with Robles BioCeutics to protect their innovative GlowSelle™ platform has been a privilege. This PCT patent application filing aims to secure proprietary rights to their pioneering injury-mimetic technology, paving the way for transformative advancements in regenerative skincare. We’re thrilled to help safeguard their vision for a healthier, more vibrant future,” said Jason Jardine, Partner at Knobbe Martens.
“The patent filing underscores Robles BioCeutics’ commitment to advancing safe, science-backed skincare solutions rooted in senolytic and stem cell-derived technologies. By mimicking the body’s natural regenerative signals, GlowSelle™ is designed to stimulate collagen production, reduce inflammation, and restore skin vitality — setting a new standard in evidence-based anti-aging innovation,” said Dr. Jorge Genovese, Chief Scientific Officer of the Company.
“I extend my deepest gratitude to our exceptional team and Knobbe Martens for their pivotal role in securing the PCT patent for our transformative GlowSelle™ technology. By amplifying the body’s own healing signals, we are pioneering a new era of regenerative dermatology, delivering scientifically robust solutions that redefine skin health with unparalleled efficacy,” said Maria Robles, President and CEO of Robles BioCeutics.
About Robles BioCeutics
Robles BioCeutics is a regenerative dermatology company committed to redefining skin health through innovative science in stem cell–derived technologies and senolytic research. By addressing aging where it begins — at the cellular level — the company develops solutions that are both effective and rooted in human safety, designed to revitalize, protect, and rejuvenate.
About Knobbe Martens
Knobbe Martens is the leading U.S. intellectual property (IP) law firm founded in 1962, specializing in patent, trademark, and technology law. With a large roster of attorneys and scientists, the firm handles a range of IP services, from patent prosecution to litigation, serving a global client base of corporations and emerging businesses. The firm maintains offices across California and other major U.S. cities, including New York, Seattle, and Washington D.C
For updates, follow Robles BioCeutics on Instagram, LinkedIn, Twitter, Facebook, and Youtube, or visit us at https://roblesbioceutics.com/.
Media Contact: Maria Robles, CEO and President
Robles BioCeutics
858-609-0948
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/robles-bioceutics-teams-up-with-top-tier-intellectual-property-law-firm-knobbe-martens-to-protect-first-in-class-age-reversing-stem-cell-technology-302565871.html
SOURCE Robles BioCeutics
